CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

BACKGROUND: Probody® therapeutics are antibody prodrugs designed to be activated by tumor-associated proteases. This conditional activation restricts antibody binding to the tumor microenvironment, thereby minimizing ‘off-tumor’ toxicity. Here, we report the phase 1 data from the first-in-human stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanborn, Rachel E, Hamid, Omid, de Vries, Elisabeth GE, Ott, Patrick A, Garcia-Corbacho, Javier, Boni, Valentina, Bendell, Johanna, Autio, Karen A, Cho, Daniel C, Plummer, Ruth, Stroh, Mark, Lu, Lawrence, Thistlethwaite, Fiona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311331/
https://www.ncbi.nlm.nih.gov/pubmed/34301808
http://dx.doi.org/10.1136/jitc-2021-002446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311331/
https://www.ncbi.nlm.nih.gov/pubmed/34301808
http://dx.doi.org/10.1136/jitc-2021-002446

Ejemplares similares